newsfilter
← Earnings
Earnings Releases·

Aclaris Therapeutics — October 27, 2026 Earnings Summary

  • ATI-052 Phase 1b data demonstrated robust efficacy in Atopic Dermatitis (45% placebo-adjusted EASI score change, 78% EASI-50 response) and Asthma (59% FeNO reduction, 200ml FEV1 improvement) with a favorable safety profile and no Grade 3/4 adverse events.
  • The company intends to prioritize Phase 2b development of ATI-052 in Eosinophilic Esophagitis (EoE), with trial initiation planned for early next year, while an update on additional indications is expected in the near term.
  • No financial performance metrics (revenue, earnings, or cash flow) were disclosed as the company remains in the clinical stage; the press release focuses exclusively on clinical trial outcomes and strategic development plans.
  • Management highlighted ATI-052's potential best-in-class status driven by unique slow-dissociation kinetics (116x longer residence time than comparators) and extended half-life via FcRn engineering.
Company
ACLARIS THERAPEUTICS INC
Sector
Healthcare
Industry
Diagnostics & Research